Exclusive Summary

• Bridges the global market vacuum left by the originator's discontinuation, capturing the robust demand for affordable oncology supportive care in emerging markets.
• Offers highly attractive health economics compared to expensive TPO-RAs and scarce platelet transfusions, making it structurally advantaged for public tender success in price-sensitive regions.
• Targets the massive pool of over 20 million new global cancer cases annually, directly addressing the critical clinical need to manage chemotherapy-induced thrombocytopenia (CIT).
• Dual dosage availability (3mg and 5mg) ensures clinical dosing flexibility, backed by mature Chinese biomanufacturing and ready-to-file dossiers for swift distributor registration.